Innate Pharma Shares Are Trading Higher After the Company Announced Its TELLOMAK Phase 2 Trial of Lacutamab Demonstrated Significant Symptom Relief and Quality of Life Improvements.
Innate Pharma Shares Are Trading Higher After the Company Announced Its TELLOMAK Phase 2 Trial of Lacutamab Demonstrated Significant Symptom Relief and Quality of Life Improvements.
Innate pharma的股票在公司宣佈其TELLOMAk 2期試驗的Lacutamab顯示出顯著的症狀緩解和生活質量改善後上漲。
Innate Pharma Shares Are Trading Higher After the Company Announced Its TELLOMAK Phase 2 Trial of Lacutamab Demonstrated Significant Symptom Relief and Quality of Life Improvements.
Innate pharma的股票在公司宣佈其TELLOMAk 2期試驗的Lacutamab顯示出顯著的症狀緩解和生活質量改善後上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。